PROfound Puts Lynparza On Track For Prostate Cancer Indication

 
• By Sten Stovall
Cancer_Cell
Lynparza could become the first PARP inhibitor in prostate cancer. • Source: Shutterstock

More from Clinical Trials

More from R&D